Loading..

Aurinia Pharmaceuticals Inc. Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

2022-06-03 11:05:00

Aurinia Pharmaceuticals Inc. presented data demonstrating the efficacy of LUPKYNIS® (voclosporin) for the treatment of people with lupus nephritis (LN), a serious complication of systemic lupus erythematosus (SLE), in achieving the proteinuria treatment targets recommended by the European Alliance of Associations for Rheumatology (EULAR) and the European Renal Association (ERA). A post-hoc analysis of pooled data from the similarly designed 48-week AURA-LV and 52-week AURORA 1 studies were presented in an oral session at the EULAR 2022 European Congress of Rheumatology by Hans-Joachim Anders, M.D., Professor of Nephrology at the University of Munich (LMU). The pooled analysis from the Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessed the efficacy of voclosporin, in addition to mycophenolate mofetil (MMF) and low-dose steroids, to reduce urine protein creatinine ratio (UPCR) to achieve the following EULAR/ERA treatment targets updated in 2019: =25% reduction in UPCR by three months, =50% reduction in UPCR by six months, UPCR =0.7 mg/mg by 12 months, as well as steroid dose of =7.5 mg/day at 12 months. The breakdown of the reductions in UPCR at month three, six, and 12 is as follows: At three months, 78.4% of patients in the voclosporin group and 62.4% of patients in the control group achieved =25% reduction in UPCR (OR 2.25, ??CI 1.52-3.33, p<0.0001). At six months, 66.0% of patients in the voclosporin group and 47.0% of patients in the control group achieved =50% reduction in UPCR (OR 2.24, CI 1.57-3.21, p<0.0001). At 12 months, 52.6% of patients in the voclosporin group and 33.1% of patients in the control group achieved UPCR =0.7 mg/mg (OR 2.52, CI 1.75-3.63, p<0.0001). At 12 months, 89.6% of the voclosporin group and 82.8% of the control group achieved the recommended steroid dose of =0.75 mg/day according to the protocol-defined steroid taper (OR 1.83, CI 1.03-3.27, p=0.0396). In addition, the proportion of patients meeting UPCR =0.7 and steroid dose =7.5 mg/day was 44.4% in the voclosporin group and 27.1% in the control group (OR 2.42, CI 1.66-3.53, p<0.0001).

Aurinia Pharmaceuticals Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM

2022-06-01 11:06:00

Aurinia Pharmaceuticals Inc. Presents at DGE's 2nd KOL & Thought Leader Engagement Summit, Jun-01-2022 09:15 AM. Speakers: Keely Dahl, Associate Medical Director.

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022

2022-06-01 10:15:00

Dynamic Global Events LLC, DGE's 2nd KOL & Thought Leader Engagement Summit, Jun 01, 2022 through Jun 02, 2022.

Rosen Law Firm Files Class Action Lawsuit on Behalf of Purchasers of the Securities of Aurinia Pharmaceuticals Inc

2022-05-24 22:15:00

Rosen Law Firm announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aurinia Pharmaceuticals Inc. between May 7, 2021 and February 25, 2022, inclusive (the "Class Period"). A class action lawsuit has already been filed. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Aurinia was experiencing declining revenues; (2) Aurinia's 2022 sales outlook for LUPKYNIS would fall well short of expectations; (3) accordingly, Aurinia had significantly overstated LUPKYNIS's commercial prospects; (4) as a result, Aurinia had overstated its financial position and/or prospects for 2022; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Aurinia Pharmaceuticals Inc. Presents Results from the Two-Year Aurora 2 Continuation Study At the 2022 European Renal Association (Era) Congress

2022-05-20 16:07:00

Aurinia Pharmaceuticals Inc. announced for the first time the results of the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS(TM) (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus (SLE). The results were presented during an oral session at the 59th European Renal Association (ERA) Congress, held in Paris and virtually May 19-22, 2022. The AURORA 2 study assessed long-term safety and tolerability of voclosporin compared to placebo (both taken in combination with mycophenolate mofetil (MMF) and low-dose oral steroids) in patients with LN receiving treatment for an additional 24 months following completion of one year on treatment in the AURORA 1 study. The primary endpoint was safety and included assessments of adverse events, deaths, and hematological assessments. Secondary endpoints include renal response, renal flare, renal outcomes, and changes in urine protein to creatinine ratio (UPCR) and estimated glomerular filtration rate (eGFR). Voclosporin was well tolerated during the study period with a similar safety profile to control and no unexpected safety signals. Specific findings included: Ovall r rates of serious adverse events were similar in both the control (28%) and voclosporin (26.0%) armrms and there was no increase in infectious events. Generally adverse events were low and decreased over time on treatment. Significant and meaningful reductions in proteinuria achieved in AURORA 1 were maintained. In AURORA 2, there was a significant difference in eGFR slope in favor of voclosporin (-0.2 mL/min/1.73 m2) compared to control arm (-5.4 mL/min/1.73 m2). There was a small, expected, and early decrease in mean eGFR in the first four weeks of treatment in AURORA 1, after which eGFR remained stable through the end of AURORA 2. The mean UPCR was lower in the voclosporin-treated groups at all time points during the three years. There were four deaths in the active control group during AURORA 2, while none in the voclosporin-treated group. A post-hoc analysis of pooled data from the AURA-LV and AURORA 1 studies was also presented during an oral session at the ERA Congress and examined the impact of voclosporin on the time to proteinuria reduction by biopsy class. The analysis reviewed pure class III, class IV, and class V biopsy groups and showed patients treated with voclosporin in addition to MMF and low dose steroids achieved earlier reductions in proteinuria across biopsy classes. These results support the efficacy results observed in the AURA-LV and AURORA 1 trials respectively, indicating a faster time to response when voclosporin is added to MMF and low-dose steroid treatment. AURORA 2 Study Design AURORA 2 (NCT03597464) is a Phase 3 randomized, double-blind, placebo-controlled clinical trial to assess the long-term safety and tolerability of voclosporin, in addition to MMF/steroids. Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with MMF at 1 g twice daily with low-dose oral steroids, for up to an additional 24 months. A total of 216 LN patients continued into AURORA 2, with 116 patients in the voclosporin-treated group and 100 patients in the active control group. About AURORA 1 The AURORA 1 study was a 52-week study designed to evaluate the efficacy and safety of LUPKYNIS (23.7 mg twice daily) when added to background therapy of MMF and corticosteroids tapered to a low dose, compared to background therapy alone in an ethnically and racially diverse patient population with active LN. Three hundred fifty-seven patients with a diagnosis of SLE and LN according to the American College of Rheumatology criteria and a kidney biopsy within two years that showed Class III, IV and/or V LN were enrolled. AURORA 1 met its primary endpoint, achieving statistically superior complete renal response rates of 41% in the LUPKYNIS group versus 23% in the control group (odds ratio [OR] 2.65, 95% confidence interval [CI] 1.64-4.27; p < 0.0001). LUPKYNIS also achieved statistical significance in all pre-specified hierarchical secondary endpoints, including reduced time to 50% reduction from baseline in UPCR and time to UPCR <0.5mg/mg compared to control. The primary endpoint was complete renal response at 52 weeks defined as urine protein creatinine ratio (UPCR) <=0.5 mg/mg, with stable renal function (defined as estimated glomerular filtration rate [eGFR] >=60 mL/min/1.73 m(2) or no confirmed decrease from baseline in eGFR of >20%), no administration of rescue medication, and no more than 10 mg prednisone equivalent per day for three or more consecutive days or for seven or more days during Weeks 44 through 52. LUPKYNIS was well tolerated with no unexpected safety signals. Serious adverse events (SAEs) were reported in 21% of those treated with LUPKYNIS and in 21% of those in the control group. Results from the completed AURORA 1 study (NCT03021499) were published in May 2021 in The Lancet.

Aurinia Pharmaceuticals Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022

2022-05-17 08:50:00

Aurinia Pharmaceuticals Inc. Presents at EULAR Congress 2022, Jun-01-2022 through Jun-04-2022. Venue: Bella Center Copenhagen, Center Boulevard 5, Copenhagen, Denmark. Presentation Date & Speakers: Jun-03-2022, Amit Saxena, M.D., NYU School of Medicine, Hans-Joachim Anders, Professor of Nephrology and Head of Renal Division, University of Munich.

Aurinia Pharmaceuticals Inc. Presents at 59th ERA Congress 2022, May-19-2022 through May-22-2022

2022-05-17 08:49:00

Aurinia Pharmaceuticals Inc. Presents at 59th ERA Congress 2022, May-19-2022 through May-22-2022. Presentation Date & Speakers: May-20-2022, Anca Askanase, M.D., M.P.H., Columbia University Medical Center, Y.K. Onno Teng, President of the National Foundation of the Autoimmune Research & Collaboration Hubs.

Aurinia Pharmaceuticals Inc. Provides Earning Guidance for 2022

2022-05-10 10:00:00

Aurinia Pharmaceuticals Inc. provided earning guidance for 2022. For fiscal year 2022, the Company maintains its net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150 to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.

Aurinia Pharmaceuticals Inc. to Report Q1, 2022 Results on May 10, 2022

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q1, 2022 results Pre-Market on May 10, 2022

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022

2022-05-02 20:05:00

Aurinia Pharmaceuticals Inc., Q1 2022 Earnings Call, May 10, 2022

Pomerantz LLP Announces the Filing of Class Action Against Aurinia Pharmaceuticals Inc

2022-04-15 23:27:00

Pomerantz LLP announced that a class action lawsuit has been filed against Aurinia Pharmaceuticals Inc. and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 22-cv-02185, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Aurinia securities between May 7, 2021 and February 25, 2022, both dates inclusive (Class Period), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (Exchange Act) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: Aurinia was experiencing declining revenues; Aurinia’s 2022 sales outlook for LUPKYNIS would fall well short of expectations; accordingly, the Company had significantly overstated LUPKYNIS’s commercial prospects; as a result, the Company had overstated its financial position and/or prospects for 2022; and as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 28, 2022, Aurinia issued a release announcing its financial results for the quarter and full year ended December 31, 2021. Among other items, Aurinia reported a year-over-year revenue decline and announced a lower-than-expected sales outlook for 2022.

Aurinia Pharmaceuticals Inc., Annual General Meeting, May 17, 2022

2022-04-04 13:12:00

Aurinia Pharmaceuticals Inc., Annual General Meeting, May 17, 2022, at 12:00 US Eastern Standard Time. Agenda: To elect to the board the following nine nominees presented by the board: Dr. george m. milne, Jr., Dr. daniel billen., r. hector mackay-dunn, peter greenleaf, joseph p. hagan, Dr. david r.w. jayne, jill leversage, timothy p. walbert and Dr. brinda balakrishnan, each to serve until the 2023 annual general meeting of shareholders or until their qualified successor has been duly elected or appointed; to appoint pricewaterhousecoopers llp, chartered professional accountants, as the company's independent registered public accounting firm until the close of the 2023 annual general meeting of shareholders or until a successor is appointed; to approve, on a non-binding advisory basis, a say on pay resolution regarding the company’s executive compensation set forth in this proxy statement/circular.

Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call

2022-04-04 13:12:00

Annual General Meeting

MKT Tactical Fund Discloses its Views on Aurinia Pharmaceuticals

2022-03-07 00:00:00

On March 7, 2022, Aurinia Pharmaceuticals announced that MKT Tactical is campaigning for the Company to begin a strategic review. The Company stated that MKT Tactical Fund has written to the Company’s chairman asking the board to hire a bank for a sale process.

Aurinia Announces Positive Topline Results from the Aurora 2 Continuation Study of Lupkynis™ (Voclosporin) for the Treatment of Adults with Active Lupus Nephritis (Ln)

2021-12-09 11:15:00

Aurinia Pharmaceuticals Inc. announced positive topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS™ (voclosporin) for the treatment of adults with active lupus nephritis (LN), a serious complication in patients with systemic lupus erythematosus (SLE). In combination with background immunosuppressive therapy, LUPKYNIS is the first and only FDA-approved medicine with three years of pivotal trial results, including long-term safety data, within LN. Aurinia also announced the initiation of ENLIGHT-LN, a U.S.-based prospective, observational registry of adult patients with LN treated with LUPKYNIS. The registry is intended to support the interests of patients, clinicians, regulatory bodies, payers and industry by obtaining longitudinal data on LUPKYNIS. The Company aims to initiate approximately 75 sites across the U.S. Additional details regarding this registry will be provided in 2022.

Aurinia Pharmaceuticals Inc. - Special Call

2021-12-09 11:15:00

To review these AURORA 2 topline results

Aurinia Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $250 million.

2021-11-19 00:00:00

Aurinia Pharmaceuticals Inc. has filed a Shelf Registration in the amount of $250 million. Security Name: Common Shares Security Name: Debt Securities Security Name: Warrants Transaction Features: Omnibus/Universal Shelf Registration

Aurinia Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM

2021-11-10 21:21:00

Aurinia Pharmaceuticals Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom.

Aurinia Pharmaceuticals Inc. Presents at ASN Kidney Week 2021, Nov-04-2021

2021-11-04 00:00:00

Aurinia Pharmaceuticals Inc. Presents at ASN Kidney Week 2021, Nov-04-2021 .

Aurinia Pharmaceuticals Inc. Reaffirms Revenue Guidance for 2021

2021-11-03 10:00:00

Aurinia Pharmaceuticals Inc. reaffirmed revenue guidance for 2021. The company maintains its previously stated annual revenue estimate in the range of $40 to $50 million for 2021.

Aurinia Pharmaceuticals Inc. Announces Updated Interim Results from the Aurora 2 Continuation Study of Lupkynis (Voclosporin) for the Treatment of Lupus Nephritis

2021-11-01 14:12:00

Aurinia Pharmaceuticals Inc. announced updated interim results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of LUPKYNIS (voclosporin) for the treatment of lupus nephritis (LN) in patients with systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. The updated results will be presented virtually on Nov. 8 during Plenary Session III at 10:45 a.m. EST during The American College of Rheumatology (ACR) Convergence 2021. In the interim analysis, patients in the voclosporin group maintained meaningful reductions in proteinuria. From pre-treatment baseline in AURORA 1 to month 30 in AURORA 2, mean urine protein/creatinine ratio (UPCR) was -3.32 mg/mg for the voclosporin group (n=90) and -2.55 mg/mg for the control group (n=78). In the voclosporin group, estimated glomerular filtration rate (eGFR), an important measurement of kidney function, remained stable through month 30. There were no unexpected new adverse events reported in the voclosporin group compared to the control group. AURORA 2 (NCT03597464) is a Phase 3 randomized, double-blind, placebo-controlled clinical trial to assess the long-term safety and tolerability of voclosporin, in addition to the standard of care, for the treatment of LN in patients with SLE. Patients who completed 12 months of treatment in the Phase 3 AURORA 1 study were eligible to enroll in the AURORA 2 continuation study with the same randomized treatment of voclosporin at 23.7 mg twice daily or placebo, in combination with mycophenolate mofetil (MMF) at 1 g twice daily with either no or low-dose oral steroids, for an additional 24 months. A total of 216 LN patients continued into AURORA 2, with 116 patients in the voclosporin group and 100 patients in the control group. 90 and 78 patients, respectively, received 30 months of total treatment as of this interim analysis. Final results from the AURORA 2 study are expected by the end of 2021. Results from the completed Phase 3 randomized, double-blind, placebo-controlled, multicenter AURORA 1 study (NCT03021499) were recently published in The Lancet.

GSK Denies Mail Report of Interest in Aurinia

2021-11-01 09:43:00

GlaxoSmithKline (GSK.L) on November 01, 2021 dismissed a Mail on October 31, 2021 report that said that the British pharma group could be interested in bidding for Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH). Britain's Mail on October 31, 2021 newspaper said, citing mounting speculation, that GSK is preparing a bid for Canada's Aurinia. The report is not true, a GSK spokesperson said in an email.

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022

2021-10-29 14:57:00

SVB Leerink LLC, 11th SVB Leerink Annual Global Healthcare Conference 2022, Feb 14, 2022 through Feb 18, 2022. Venue: New York, New York, United States.

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc., Q3 2021 Earnings Call, Nov 03, 2021

Aurinia Pharmaceuticals Inc. to Report Q3, 2021 Results on Nov 03, 2021

2021-10-27 11:22:00

Aurinia Pharmaceuticals Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021

Bristol-Myers Reportedly Makes Takeover Approach to Aurinia Pharmaceuticals

2021-10-22 00:00:00

Bristol-Myers Squibb Company (NYSE:BMY) has expressed interest in acquiring Aurinia Pharmaceuticals Inc. (NasdaqGM:AUPH), according to people familiar with the matter. The company recently approached Aurinia about a deal, said the people, who asked to not be identified because the matter isn’t public. No final decision has been made and Bristol-Myers could opt against any potential deal, they said.

American Society of Nephrology, Inc., ASN Kidney Week 2021, Nov 04, 2021 through Nov 07, 2021

2021-10-15 12:00:00

American Society of Nephrology, Inc., ASN Kidney Week 2021, Nov 04, 2021 through Nov 07, 2021.

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to S&P Global BMI Index

2021-09-20 00:00:00

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to S&P Global BMI Index

Aurinia Pharmaceuticals Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 02:55 PM

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep-20-2021 02:55 PM.

Aurinia Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:40 PM

2021-09-15 17:11:00

Aurinia Pharmaceuticals Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-30-2021 12:40 PM. Venue: New York, United States.

Aurinia Pharmaceuticals Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 03:00 PM

2021-09-10 17:30:00

Aurinia Pharmaceuticals Inc. Presents at H.C. Wainwright 23rd Annual Global Investment Conference, Sep-13-2021 03:00 PM. Venue: Lotte New York Palace Hotel, New York City, New York, United States.

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-Related Diseases

2021-08-17 10:05:00

Aurinia Pharmaceuticals Inc. announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. AUR200: Recombinant Fc Protein Targeting BAFF/APRIL: The first program, AUR200, was acquired by way of Aurinia purchasing all of the common stock of Thunderbolt Pharma Inc. (Thunderbolt), a private company. AUR200 is a recombinant Fc fusion protein designed to specifically block B-cell Activating Factor, known as BAFF, and A Proliferation-Inducing Ligand, known as APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions. For the acquisition, Aurinia made an aggregate upfront payment of $750,000 USD to the shareholders of Thunderbolt and will be responsible for future re upon investigational new drug (IND) acceptance by the United States’ Food and Drug Administration (FDA) or any equivalent authority. Additionally, Thunderbolt shareholders will receive low single digit royalties on any future net sales. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA by the end of 2022. AUR300: M2 macrophage modulation via CD206 binding: The second program, AUR300, was secured through a global licensing and research agreement with Riptide Bioscience Inc. (Riptide), a private company. AUR300 is a novel peptide therapeutic that modulates M2 macrophages (a type of white blood cells) via the macrophage mannose receptor CD206. Dysregulation of M2 macrophages drives fibrosis. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines, and therefore may have significant clinical applications for autoimmune and fibrotic diseases. Riptide has longstanding expertise in interpreting the etiology of fibrosis, including the discovery of lysyl oxidase and procollagen. As part of the agreement, Aurinia paid Riptide an upfront fee of $6 million USD. Additional milestone payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization. It is anticipated that clinical development for AUR300 will commence during the first half of 2023.

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0.8 million.

2021-08-17 00:00:00

Aurinia Pharmaceuticals Inc. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0.8 million on August 17, 2021. The acquisition also includes AUR200: Recombinant Fc Protein Targeting BAFF/APRIL. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA by the end of 2022. In a related transaction, Aurinia Pharmaceuticals secured AUR300: M2 macrophage modulation via CD206 binding through a global licensing and research agreement with Riptide Bioscience Inc. Aurinia Pharmaceuticals Inc. (TSX:AUP) completed the acquisition of Thunderbolt Pharma Inc from shareholders on August 17, 2021.

Aurinia Pharmaceuticals Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:50 PM

2021-08-04 12:33:00

Aurinia Pharmaceuticals Inc. Presents at BTIG Virtual Biotechnology Conference, Aug-10-2021 02:50 PM. Speakers: Glenn Schulman, Senior Vice President of Corporate Communications & Investor Relations, Joseph M. Miller, Chief Financial Officer, Massimiliano Colao, Chief Commercial Officer, Neil Solomons, Chief Medical Officer, Peter S. Greenleaf, President, CEO & Director.

Aurinia Pharmaceuticals Inc. to Report Q2, 2021 Results on Aug 05, 2021

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc. announced that they will report Q2, 2021 results After-Market on Aug 05, 2021

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 05, 2021

2021-07-26 10:05:00

Aurinia Pharmaceuticals Inc., Q2 2021 Earnings Call, Aug 05, 2021

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P Global BMI Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P Global BMI Index

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Completion Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Completion Index

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Composite Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Composite Index

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Capped Composite Index

2021-07-24 00:00:00

Aurinia Pharmaceuticals Inc.(TSX:AUP) dropped from S&P/TSX Capped Composite Index

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021

2021-07-21 14:31:00

Oppenheimer & Co. Inc., Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, Sep 20, 2021 through Sep 23, 2021.

Aurinia Pharmaceuticals Announces Delisting from the Toronto Stock Exchange

2021-07-16 21:30:00

Aurinia Pharmaceuticals Inc. announced it will voluntarily delist the common shares of the Company from the Toronto Stock Exchange (TSX) effective as of the close of trading on July 30, 2021. The Company’s common shares will no longer be traded on the TSX but will continue to trade on the Nasdaq Capital Market (Nasdaq) under the symbol AUPH. Trading on the Nasdaq accounted for approximately 94 percent of Aurinia’s daily trading volume over the past 12 months. Therefore, the Company believes that the trading volume of its shares on the TSX no longer justifies the expense and administrative efforts associated with maintaining a dual listing. The Company is confident that the transition to a single listing will help deliver better value to its shareholders, employees and of course, the patient and HCP communities it serves. Pursuant to Sec. 720(b) of the TSX Company Manual, shareholder approval is not required as an acceptable alternative market exists for the listed securities.

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021

2021-07-01 10:09:00

BTIG, LLC, BTIG Virtual Biotechnology Conference, Aug 09, 2021 through Aug 10, 2021.